Human dynamin-like, interferon-induced myxovirus resistance 2 (Mx2/MxB) is a potent inhibitor of HIV-1 infection and a potential agent for the treatment of HIV/AIDS. MxB directly interacts with the HIV-1 capsid and blocks nuclear import of pre-integration complexes and subsequent chromosomal integration of the viral cDNA. Anti-HIV-1 activity and capsid-binding require the N-terminal domain of MxB and protein oligomerization, yet each of these has eluded structural determination due to difficulties in protein preparation. We purified a GTPase active MBP fusion of the full-length wild-type MxB from mammalian cells. The full-length MxB purifies as discrete oligomers and further self-assembles into helical arrays in physiological salt. Intriguingly, GTP, but not GDP, binding to MxB results in array disassembly, while subsequent GTP hydrolysis allows its re-formation. Using cryoEM, we determined the MxB assembly structure at 4.6 Å resolution, revealing novel oligomerization and higher-order assembly interfaces that were absent or are distinct from the crystal structure of MxB that lacked the Nterminal domain and harbored interface mutations. The structure suggests that salt bridges mediate MxB higher-order assembly, which is disrupted by GTP-induced conformational changes. More importantly, mutational analysis combined with viral infectivity assays revealed that MxB oligomers, not the dimer or higher-order assemblies, are in fact the active species against HIV-1 infection. The near-atomic wild-type MxB structure provides a vital framework for re-evaluating conflicting results regarding the effects of MxB oligomerization and GTPase activity on its anti-HIV-1 activity. Moreover, this first high-resolution assembly structure among the superfamily of dynamin-like large GTPases allows us to propose a new GTP-dependent assembly/disassembly model, distinct from current models.
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